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INTRODUCTION
Increased frequency of acute events and comorbidities
in advanced heart failure is a template for increased
mortality and morbidity.1,2 Hospital admission of
patients with heart diseases across Africa is often due
to acute decompensated heart failure, 3 and
notwithstanding the availability of a plethora of
disease-modifying medical therapy, patients with heart
failure are at high risk of  poor clinical outcomes.4-6 A
significant number of deaths in heart failure patients is
due to sudden cardiac death, which may be caused by
arrhythmias  which can further be worsened by
anaemia.7,8
Several factors, including immunological, neuro-
hormonal and metabolic factors, have been implicated
in the progression of heart failure.9 In addition, anaemia
and renal failure seem to be the major risk factors for
adverse cardiovascular outcome.10 In a vicious triad
called cardio-renal anaemia syndrome (CRAS), primary
heart failure with secondary dysfunction in the kidneys,
without primary structural kidney damage, causes
development of anaemia. 11 The major factors
contributing to anaemia in heart failure include
nutritional deficiencies such as iron deficiency,
inflammation, chronic kidney dysfunction, and
haemodilution.9,10 Anaemia is associated with several
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ABSTRACT
Background: Heart failure often coexists with many comorbidities, including
anaemia. However, the pattern of  anaemia in heart failure and its clinical
and echocardiographic associations have not been adequately studied among
Nigerians.
Objective: To describe the pattern of  anaemia, its clinical characteristics,
and its echocardiographic associations among heart failure subjects in Nigeria
Methods: One hundred and forty subjects with heart failure were recruited
from the cardiology clinics of two teaching hospitals in southwest Nigeria:
Ladoke Akintola University of  Technology and Bowen University Teaching
Hospitals, Ogbomoso. Complete blood analyses, among other tests, were
done. Statistical analysis was done with Statistical Package for the Social
Sciences (SPSS) 20.0. P <0.05 was taken as statistically significant.
Result: Anaemia, as defined by the World Health Organisation, occurred in
106 (75.7%) of  the heart failure patients. The patterns of  anaemia among
participants include combined anaemia of chronic diseases (ACD) with iron
deficiency in 64 (45.7%) patients, and ACD alone in 40 (28.6%). Anaemia was
more significantly associated with previous diagnosis of diabetes mellitus,
presence of  pulmonary hypertension, and heart failure with reduced ejection
fraction. Mean systolic and diastolic blood pressures, ejection fraction, and
fractional shortening were significantly lower among heart failure subjects
with anaemia, while serum creatinine, left atrial dimension, left ventricular
end diastolic dimension, and left ventricular mass index were significantly
higher among heart failure subjects with anaemia compared to those without
anaemia.
Conclusion: Anaemia occurs very frequently among heart failure patients in
southwest Nigeria. It is associated with many poor prognostic factors,
including diabetes mellitus, pulmonary hypertension, and kidney failure.
PATTERN OF ANAEMIA AND ITS CORRELATES IN NIGERIANS
WITH HEART FAILURE
Ann Ibd. Pg. Med 2020. Vol.18, No.1 51-59
                                                   Annals of Ibadan Postgraduate Medicine. Vol. 18 No. 1, June 2020   52
structural, functional, and geometric cardiac
abnormalities, some of  which may initially be
compensatory of the anaemia but may eventually be
counterproductive in the progression of heart failure.
Echocardiography in heart failure can be used to assess
various structural, functional, and geometric
abnormalities, including those that are associated with
anaemia. However, the prevalence of anaemia in
several registries from the African continent varies in
most cases due to varied definitions of anaemia and
emphasis on severe anaemia.12-15
Despite the wide use of echocardiography in most
tertiary centres in Nigeria, the pattern of anaemia in
heart failure and its clinical and echocardiographic
associations have not been adequately studied among
Nigerians. This study therefore aimed at describing the
different patterns of anaemia among Nigerians with
heart failure, its clinical and echocardiographic
associations, and its determinants among heart failure
subjects attending the cardiology clinics of  two
Nigerian tertiary health care settings.
METHODS
This was a cross-sectional study done at the cardiology
clinics of  Ladoke Akintola University of  Technology
Teaching Hospital, Ogbomoso, and Bowen University
Teaching Hospital, Ogbomoso, Nigeria. One hundred
and forty patients with heart failure were included in
the study by simple randomization technique. The study
was conducted from August 2018 to February 2019.
At study entry, each potential candidate was screened
and recruited if they fulfilled the inclusion criteria. The
data collection form was used to record the patients’
data. Blood samples were collected and analysed for
various haematological parameters, including packed
cell volume, haemoglobin concentration (Hb), mean
corpuscular haemoglobin concentration, serum
transferrin, total iron, total iron binding capacity,
transferrin saturation, ferritin, white cell count, platelet
count, and peripheral blood film appearance. All the
samples were centrally analysed at LAUTECH
Teaching Hospital, Ogbomoso. Anaemia was defined
as Hb <12g/dl in women and <13g/dl in men
according to the World Health Organisation (WHO)
criteria. Heart failure was diagnosed based on the 2016
updated guidelines of the European Society of
Cardiology on the diagnosis and management of  heart
failure.16 The inclusion criteria included subjects (1) who
were >18 years of age; (2) who had primary diagnosis
of heart failure of more than 6 months duration; (3)
who were attending the cardiology clinics of  Ladoke
Akintola University of  Technology Teaching Hospital,
Ogbomoso, and Bowen University Teaching Hospital,
Ogbomoso, Nigeria; (4) who willingly gave their
consent to participate; and (5) who were willing to be
followed up.
Exclusion criteria included patients with comorbid
illness such as advanced chronic kidney disease (with
estimated glomerular filtration rate (eGFR) <15 ml/
min); patients with history of recent blood transfusion,
pregnancy, mental diseases, and abuse of  non-steroidal
anti-inflammatory drugs; patients with ongoing
infection; or patients who had been admitted for any
illness in the last two weeks prior to recruitment. The
Kansas City Cardiomyopathy Questionnaire (KCCQ)
score was used to assess quality of life, while six-minute
walk test (the distance covered in six minutes of
supervised walk in the clinic setting under observation)
was used to describe the functional status of each
participant.
Information that were obtained include name, age,
gender, occupation, marital status, address, and tribe.
Histories of hypertension, diabetes, smoking, and
alcohol intake, and family history of hypertension/
diabetes were also taken. Investigations that were done
include trans-thoracic echocardiography, serum
electrolytes, urea and creatinine, and urinalysis. Body
mass index (BMI) was determined and categorized
appropriately. 17
Estimated glomerular filtration rate was calculated
using the Cockcroft- Gault formula.11 Functional
classification according to the New York Heart
Association (NYHA) classification as class I-IV was
used. 18 Twelve-lead resting electrocardiography was
done and interpreted according to Minnesota coding.19
Echocardiography was done using the General Electric
Logic 9 machine according to the American Society
of Echocardiography guideline20 with the patient in
appropriate position. All the echocardio-graphies were
done at Ladoke Akintola University of  Technology
Teaching Hospital, Ogbomoso. Parameters that were
measured include left ventricular internal dimension in
diastole (LVIDd), left ventricular end systolic
dimension (LVSD), posterior wall thickness dimension
in diastole, interventricular septal thickness in diastole
(IVSd), right ventricular dimension, and left atrial
dimension. Ejection fraction and fractional shortening
were determined according to Teichholz formula.
Ejection fraction was used to categorize heart failure
into the three different phenotypes as heart failure with
reduced ejection fraction (HFrEF), heart failure with
mid-range ejection fraction (HFmrEF), and heart
failure with preserved ejection fraction (HFpEF).
Left ventricular mass (LVM) and left ventricular mass
index (LVMI) were determined according to
standardized formula.21 Left ventricular geometry was
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determined using the relative wall thickness (RWT) and
the left ventricular mass. Normal geometry occurs when
both RWT and LVM are normal. Concentric
remodelling is when RWT is increased and LVM is
normal, while eccentric hypertrophy is when LVM is
increased with normal RWT. When RWT and LVM
are both increased, the geometry is defined as concentric
left ventricular hypertrophy. 21 Ethical approval was
obtained from the ethics committees of Ladoke
Akintola University of  Technology Teaching Hospital,
Ogbomoso, and Bowen University Teaching Hospital,
Ogbomoso. All study participants also gave written
informed consent.
Statistical analysis
All data were entered into the Statistical Package for
Social Sciences (SPSS) version 20.0 (Chicago Ill. USA)
Quantitative variables were summarized as means ±
standard deviation, while qualitative variables were
summarized as frequencies (percentages). Student’s t
test and analysis of  variance (ANOVA) were used to
determine the statistical significance of  differences
between groups of continuous variables, while Chi
square was used for categorical variables. Pearson
correlation statistics was used to determine univariate
correlation between variables.
RESULTS
The clinical, demographic, and laboratory parameters
of  participants are shown in Table 1. Heart failure
patients with anaemia were significantly older compared
to those without anaemia (64.9 ± 15.7 vs. 56.8 ± 17.0
years respectively, p<0.05). Systolic blood pressure
(122.4± 22.6 vs. 133.7± 20.2 mmHg, p<0.05), diastolic
blood pressure (76.7 ± 13.8 vs. 83.1 ± 13.9 mmHg,
p=0.019), eGFR (49.0 ± 35.6 vs. 70.2 ± 50.4 ml/
min/1.732m2, p= 0.048), mean BMI (23.9 ±6.1 vs.
27.4 ±6.7kg/m2, p= 0.010), and mean total platelet
count (174.5 ± 95.5 vs. 213.7 ±94.4 /mm3, p=0.034)
were significantly lower among heart failure patients
with anaemia compared to those without anaemia.
Mean heart rate (96.9 ± 20.2 vs. 88.2 ±14.3/min,
p=0.047), mean fasting blood sugar (6.8 ±2.2 vs. 6.0
±1.2mmol/l, p =0.0026), prevalence of previous
diagnosis of  diabetes mellitus (7.54% vs. 0.0%, p=
0.017), and prevalence of  proteinuria (44.3% vs. 20.6%,
p=0.008), were significantly higher among heart failure
subjects with anaemia. Presence of intracardiac clots
or vegetative masses was also significantly more
frequent among heart failure subjects with anaemia
compared to those without anaemia as shown in Table
1.





Age (years) 64.9 ± 15.7 56.8 ± 17.0 0.011*
Gender (Males, n) 43 (40.6%) 17 (50.0%) 0.333
SBP (mmHg) 122.4± 22.6 133.7± 20.2 0.010*
DBP (mmHg) 76.7 ± 13.8 83.1 ± 13.9 0.019*
Heart rate (/min) 96.9 ± 20.2 88.2 ±14.3 0.047*
Urea (mmol/l) 18.9±22.6 10.9±22.7 0.200
Creatinine (μmol/l) 129.4± 129.0 117.7±67.9 0.722
Fasting blood sugar (mmol/l) 6.8 ±2.2 6.0 ±1.2 0.0026*
eGFR 49.0 ± 25.6 70.2 ± 50.4 0.048*
Hx of hypertension (n) 94 (88.7%) 28 (82.4%) 0.338
Hx of DM (n) 8 (7.54%) 0 (0%) 0.017*
NYHA III/IV (n) 70 (66.0%) 23 (67.6%) 0.614
Use of ACE-Is or ARBs (n) 87 (82.1%) 32 (94.1%) 0.064
Body mass index (kg/m2) 23.9 ±6.1 27.4 ±6.7 0.010*
WBC Count (x 109/mm3) 4.2 ± 1.5 4.7 ± 2.1 0.123
Platelets count (/mm3) 174.5 ± 95.5 213.7 ±94.4 0.034*
Proteinuria (n) 47(44.3%) 7(20.6%) 0.008*
Obesity (n) 18(17.0%) 9(26.5%) 0.034*
ECG LVH (n) 69(65.1%) 20(58.8%) 0.509
Intracardiac vegetation (n) 4 1 0.019*
Intracardiac clots (n) 32 4 0.016*
Table 1: Clinical characteristics of  study participants, prescription pattern, and associated prognostic factors
* statistically significant
Key to table:
SBP–systolic blood pressure, DBP–diastolic blood pressure, ECG–electrocardiography,
WBC–white blood cell, NYHA–New York Heart Association, DM–diabetes mellitus,
eGFR–estimated glomerular filtration rate, ACE-I–angiotensin-converting enzyme inhibitor,
ARB–angiotensin receptor blocker, Hx–history
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Normal DD (n) 36(34.0%) 11(32.4%) 0.866
HFrEF (n) 62(58.5%) 10(29.4%) 0.008*
Pulmonary hypertension (n) 55(51.9%) 4(11.8%) 0.001*
LVIDd (mm) 57.8 ± 11.4 52.1 ± 9.7 0.025*
Left atrial dimension(mm) 47.9 ± 11.5 45.8 ±12.0 0.437
Mean Ejection fraction (%) 38.8± 8.2 47.4 ± 10.4 0.000**




CH (n) 34(32.1%) 19(55.9%) 0.048*
CR (n) 15(14.2%) 7(20.6%)
EH (n) 46(43.4%) 8(23.5%)
N (n) 11(10.4%) 0
RWT 0.44 ± 0.11 0.47 ± 0.10 0.186
LVM_HT 2.7 (g/m2.7) 72.1 ± 46.8 58.5 ± 48.5 0.044*
TAPSE (mm) 16.0 ± 4.8 16.0 ± 3.4 0.973
IVSD (mm) 12.9 ±2.4 13.7 ± 2.2 0.123
6MWT (meters) 203.7± 12.7 249.9 ±20.9 0.039*




DD– diastolic dysfunction, HFrEF– heart failure with reduced ejection fraction,
LVIDd– left ventricular internal dimension in diastole, CH– concentric left ventricular hypertrophy,
CR– concentric remodelling, EH– eccentric hypertrophy, N– normal, RWT–relative wall thickness, LVM–
left ventricular mass, TAPSE– tricuspid annular pulmonary systolic excursion,
IVSD– interventricular septal thickness in diastole, 6MWT– six-minute walk test distance
Variables HFrEF (n=72) HFmrEF (n=46) HFpEF (n=22) P value
Age (years) 61.4 ± 16.0 63.8 ± 18.0 62.5 ± 15.5 0.786
PCV (%) 31.2 ± 6.8 32.1 ± 7.1 35.1 ± 4.4 0.101
Hb(g/dl) 10.4 ± 2.3 10.3 ± 2.9 11.7 ± 1.5 0.108
MCV (fL) 87.5 ± 11.0 88.2 ± 8.5 90.0 ± 6.0 0.634
MCHC (g/dl) 33.0 ± 2.4 34.8 ± 3.8 33.2 ± 2.1 0.010*
MCH (pg/cell) 29.0 ± 4.6 30.6 ± 2.8 29.8 ± 2.0 0.129
Transferrin
(mg/dl)
200.3 ± 20.6 201.0 ± 46.7 189.7 ± 14.6 0.396
Ferritin (ng/ml) 201.7 ± 159.8 285.0 ± 177.4 211.2 ± 140.6 0.044*
Total Iron (ug/dl) 39.9 ± 22.9 35.9 ± 7.7 35.3 ± 6.1 0.420
KCCQ-12
SCORE (%)
58.4 ± 16.8 63.2 ± 16.4 65.8 ± 13.9 0.034*
6MWT (meters) 203.2 ± 105.1 198.6 ± 98.0 208.3 ± 97.3 0.021*
Table 3: The demographic, haematologic and prognostic scores among heart failure phenotypes
* statistically significant
Key to table:
PCV– packed cell volume, Hb– haemoglobin concentration, MCV– mean corpuscular volume, MCHC–
mean corpuscular haemoglobin concentration, MCH– mean corpuscular haemoglobin, KCCQ-12– Kansas
City cardiomyopathy score, 6MWT– six-minute walk test distance
Table 2 shows the echocardiographic parameters based
on the presence or absence of anaemia. Anaemia in
heart failure was significantly more associated with
HFrEF, increased frequency of  pulmonary
hypertension, and higher LVIDd, aortic root
dimension, and LVMI as shown in Table 2. HFrEF
was more common in heart failure subjects with
anaemia (58.5% vs. 29.4%, p= 0.008) than those
without anaemia. Likewise, left ventricular internal
dimension in diastole (57.8 ± 11.4 vs. 52.1 ± 9.7 mm,
p= 0.025) and left ventricular mass indexed to height2.7
(72.1 ± 46.8 vs. 58.5 ± 48.5 g/m2.7, p= 0.044) were
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significantly higher among heart failure subjects with
anaemia compared to those without anaemia
respectively. There was no difference in the prevalence
of diastolic dysfunction among the study participants
irrespective of  their anaemia status. In the same vein,
left atrial dimension, relative wall thickness, tricuspid
annular pulmonary systolic excursion, and left
ventricular wall dimensions were similar between heart
failure subjects with anaemia and those without
anaemia as shown in Table 2. The commonest left
ventricular geometrical abnormality documented
among heart failure subjects with anaemia was eccentric
hypertrophy as it occurred in 43.4% of them, while
the commonest left ventricular geometric abnormality
among those without anaemia was concentric
hypertrophy, occurring in 55.9% of  the cohort. The
mean distance covered during the six-minute walk test
was significantly shorter among heart failure patients
with anaemia compared to those without anaemia
(203.7± 12.7 vs. 249.9 ±20.9 meters respectively,
p=0.039).
were lower among patients with HFrEF than HFmrEF
and HFpEF, but both did not achieve statistical
significance. Mean transferrin was also similar among
the three groups. However, serum ferritin was
significantly higher among patients with HFrEF, and
the KCCQ score, which is a measure of quality of
life, revealed a poorer quality of life among HFrEF
subjects compared to others as shown in Table 3.
Packed cell volume and haemoglobin concentration
were positively correlated with systolic blood pressure,
KCCQ score, and the six-minute walk distance as
shown in Table 4. Packed cell volume was only
negatively correlated with heart rate and left ventricular
mass, not haemoglobin concentration. Both packed
cell volume and haemoglobin concentration were
significantly negatively correlated with ejection fraction,
fractional shortening, and eGFR as shown in Table 4.
Variables Correlation of
PCV
P value Correlation of
Hb
P value
Age (years) -0.072 0.406 -0.108 0.165
Systolic blood pressure
(mmHg)
0.222 0.009* 0.215 0.011*
Heart rate (/min) -0.208 0.020* -0.164 0.064
LVIDd (mm) -0.150 0.107 -0.099 0.285
RVD (mm) 0.053 0.597 0.053 0.592
LAD (mm) -0.134 0.156 -0.169 0.072
EF (%) -0.245 0.008* -0.212 0.021*
Fractional shortening (%) -0.207 0.026* -0.207 0.026*
Left ventricular mass
(g/m2.7)
-0.0228 0.016* -0.180 0.057
eGFR (ml/min) -0.403 0.001* -0.410 0.000*
KCCQ (%) 0.254 0.003* 0.207 0.014*
6MWT Distance (m) 0.436 0.000* 0.228 0.035*
* statistically significant
Key to table:
LVIDd– left ventricular internal dimension in diastole, RVD– right ventricular dimension,
LAD– left atrial dimension, EF- ejection fraction, eGFR– estimated glomerular filtration rate,
KCCQ score– Kansas City Cardiomyopathy Questionnaire, 6MWT– six-minute walk test distance,
PCV– packed cell volume, Hb– haemoglobin concentration
Clinical, laboratory, and prognostic scores were
compared between the various heart failure phenotypes.
The commonest heart failure phenotype in this cohort
was HFrEF: it occurred in 72 (51.4%) patients, most
of whom were anaemic 62 (86.1%). Age was similar
between the three groups of heart failure phenotypes
even though those with HFrEF were a bit younger
than patients with the other two phenotypes. Mean
packed cell volume and haemoglobin concentrations
Table 4: Correlation statistics of  packed cell volume with some clinical and echocardiographic parameters
DISCUSSION
This study revealed that anaemia is highly prevalent
among heart failure subjects in Nigeria. The coexistence
of  anaemia with heart failure suggests poor prognosis
and advanced cardiovascular risk.2,4-5, 8-11 Heart failure
itself is associated with poor outcome, especially in
Africa where other factors such as poor health systems,
poor accessibility of current medical and surgical
options for therapy, and high out-of-pocket expenses
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may limit access to adequate care. These factors tend
to limit the scope of available therapeutic options for
heart failure subjects in Africa.8 More than three-
quarters of all heart failure patients in this study had
anaemia as defined by the World Health Organization.
This prevalence is markedly higher than what has been
reported from some other regions of the world. Goh
et al. prospectively studied 3,886 Asians with heart
failure and reported anaemia in 41% of that cohort.21
The frequency of anaemia in this study was also higher
than what was reported in a large multinational pooled
dataset of prospectively enrolled heart failure subjects,
in which the prevalence of anaemia was similar among
those with HFrEF and HFpEF (42.8% vs. 41.6%). 21
However, the prevalence of anaemia in this study is
similar to what has been reported among Indians with
chronic congestive heart failure. Arora et al. reported
that anaemia was documented in 76.7% of a cohort
of 275 patients being followed up in a hospital-based
observational study.22 57% of  subjects in Tanzania
cohorts had anaemia using the standardized definition
used in that study. 23 The prevalence in this study was
also far higher than what was reported from Kano
and Ogbomoso in 2013 where anaemia was
documented in 45% of  those subjects. However, the
cohort was a younger population (mean age of 47
years compared to the mean age of 67 years in this
study). This and the fact that heart failure patients with
anaemia were significantly older than those without
anaemia in this study suggest that anaemia occurs more
frequently with increasing age. This may be because
increasing age is a risk factor for increased frequency
of risk factors and progression of factors that can
contribute to anaemia, including nephropathy,
nutritional deficiency, recurrent infections, and
progressive blood loss.
Heart failure subjects with anaemia had significantly
worse conventional markers of poor cardiovascular
risk. Heart rate was significantly higher, systolic and
diastolic blood pressures were significantly lower,
serum creatinine was significantly higher, and fasting
blood sugar was higher among heart failure subjects
with anaemia than those without anaemia. In this study,
anaemia was also associated with poor quality of life
as shown in the significantly different KCCQ score
between heart failure patients with anaemia compared
to those without anaemia. This was similarly reported
in the study by Goh et al.
There was no significant relationship between anaemia
in heart failure and gender as there was no significant
difference between male and female participants.
However, some studies have shown that anaemia is
more prevalent in females with heart failure than males.
Hassanein M et al. showed that in an Egyptian cohort,
women were more likely to have anaemia, higher body
mass index, and more frequent atrial fibrillation than
men.24 Gender disparities have always been an issue
of interest in heart failure and many other
cardiovascular diseases. Women with heart failure have
been shown to have more preserved ejection fraction,
hypertensive aetiology of  heart failure, and comorbid
diabetes, chronic renal dysfunction, anaemia, and
depression than their male counterparts.25-26 Our
inability to demonstrate gender difference between the
frequency of anaemia in this study may be related to
the relatively older population of the cohort compared
to study populations of  most African studies. There
was no significant difference in the use of angiotensin-
converting enzyme inhibitors (ACE-Is) or angiotensin
receptor blockers (ARBs) or aspirin between heart
failure subjects with anaemia and those without
anaemia, although some authors have suggested
association of anaemia with the use of these
medications in heart failure.27
The contribution of other comorbidities to anaemia
in heart failure subjects cannot be overemphasized.
Heart failure patients with anaemia in this study
significantly had higher prevalence of diabetes and
lower eGFR than heart failure subjects without anaemia.
Diabetes is a major cause of chronic kidney disease
worldwide, and progressive diabetic nephropathy may
have contributed to the anaemia documented in heart
failure subjects who were diabetic. Similarly, other
causes of chronic kidney disease occurring among
heart failure subjects may contribute to the lower eGFR
among heart failure patients with anaemia apart from
the cardio-renal anaemia syndrome already discussed.
The major factors contributing to anaemia in heart
failure vary.28,29 This is reflected in the pattern of  anaemia
documented in this study. Anaemia of  chronic diseases
with iron deficiency was documented in 64 (45.7%)
and isolated anaemia of chronic disease in 40 (28.6%)
participants. This is similar to reports from other studies.
28 Recent researches have continued to show the role
of pro-inflammatory cytokines and altered iron
biology in the pathobiology of  anaemia and heart
failure both individually and in complement to each
other. It is also connected to other critical illnesses,
obesity, aging, cancers, kidney diseases, and auto-
immune diseases.30 Hence, heart failure is associated
with inflammation in several ways. Anaemia of  chronic
diseases with or without iron deficiency was the
commonest pattern of anaemia among heart failure
subjects in this study. This is also similar to reports
from other centres.31,32
A major contributory factor to anaemia in heart failure
is coexisting chronic kidney disease.33 Heart failure leads
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to reduced renal blood flow, and the resulting chronic
hypoxia could lead to scarring, renal damage, and
hypoxia-induced erythropoietin production with
peritubular fibroblasts proliferation. The induced
erythropoietin release does not correlate with effective
renal plasma flow and therefore leads to blunted
erythropoietin production in heart failure subjects with
anaemia. There is also erythropoietin resistance and
increased urinary loss of serum erythropoietin and
transferrin, which further make anaemia worse among
heart failure subjects.34,35 Cytokines and acute phase
proteins play important roles in the pathogenesis of
anaemia of chronic diseases with alteration in the
metabolism of iron via the molecules hepcidin and
ferritin.
The echocardiographic parameters evaluated in this
study were markers of functional, structural, and cellular
impact on the heart. Anaemia in heart failure was
associated with extensive echocardiographic changes
in structure, function, and other parameters.36 Subjects
with anaemia coexisting with heart failure were more
likely to have HFrEF than heart failure subjects without
anaemia. Similarly, mean ejection fraction and fractional
shortening were significantly lower among heart failure
patients with anaemia compared to those without
anaemia. This is similar to what has been described by
other researchers. 14,25,31 Many studies have reported
various echocardiographic changes associated with
anaemia and iron deficiency in heart failure and their
evolution after treatment.35 Among the changes seen
in the heart include atrial and ventricular remodelling,
which result in decreased contractility, alteration of
ventricular relaxation, and increased systolic pulmonary
arterial pressure. 37
Left ventricular geometry reflects structural adaptations
to various maladaptive changes in heart diseases.
Eccentric hypertrophy was more common among
heart failure patients with anaemia in this study.
Eccentric hypertrophy often heralds progressive
decline in cardiac function among hypertensive subjects,
and it is a poor prognostic factor.38 The increased
cardiovascular risk among heart failure patients with
anaemia in this study was further corroborated by the
significantly increased mean left ventricular mass, left
ventricular end diastolic dimension, and aortic root
dimension; higher frequency of pulmonary
hypertension; and lower tricuspid annular pulmonary
systolic excursion (TAPSE) compared to heart failure
patients without anaemia. Left ventricular hypertrophy
and left ventricular mass index have also been shown
to be associated with increased cardiovascular risk.8,39
Similarly, the six-minute walk test distance was
significantly lower among heart failure subjects with
anaemia, suggesting poor clinical status and a poorer
prognosis compared to those without anaemia.
A comparison of the haematologic parameters
obtained in subjects with the various heart failure
phenotypes showed that packed cell volume,
haemoglobin concentration, and mean corpuscular
volume were lower among HFrEF subjects than
subjects with other heart failure phenotypes. This finding
however did not achieve statistical significance. Mean
corpuscular haemoglobin concentration and serum
ferritin were statistically significantly lower among
subjects with HFrEF phenotype compared to others.
Similarly, quality of  life as estimated by KCCQ score
was shown to be poorer among HFrEF subjects. The
higher prevalence of anaemia associated with this heart
failure phenotype in this study may have contributed
to this finding. This further reflects the poor clinical
status of heart failure patients with anaemia, in
agreement with similar studies from other parts of
the world.40,
The major variables associated with packed cell volume
in this study were systolic blood pressure, heart rate,
ejection fraction, fractional shortening, left ventricular
mass index, KCCQ score, and the six-minute walk
test distance. This study found evidence of clinical
association of packed cell volume and haemoglobin
concentration to these parameters, and their possible
use in determining the prognosis of  anaemia in
Nigerians who have heart failure.
CONCLUSION
This study revealed that anaemia is very prevalent
among Nigerians with heart failure, with the
commonest pattern being anaemia of chronic diseases
with or without iron deficiency. Anaemia was also
shown to be associated with a poorer clinical and
temporal profile, exacerbated symptoms with
progressive renal dysfunction, increased myocardial
remodelling, worse cardiac dysfunction, and abnormal
left ventricular geometry. Further studies are required
to understand the association of anaemia with heart
failure outcomes especially among Africans, to
recognize the impact of anaemia correction on clinical
outcome, to asses when to initiate and when to cease
treatment for anaemia, and finally to estimate the safety
of  such anaemia-correcting interventions. This study
has some inherent limitations. This is an hospital- based
study and may not completely represent the population
as some of the affected subjects may not have direct
hospital contact. Also, some other chronic causes of
anaemia were not investigated which could have
contributed to the burden of anaemia among heart
failure patients.
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